<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864264</url>
  </required_header>
  <id_info>
    <org_study_id>IM012-004</org_study_id>
    <secondary_id>2016-000895-72</secondary_id>
    <nct_id>NCT02864264</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Target Engagement of BMS-986184 in Healthy Subjects and to Evaluate the Safety, Efficacy, Pharmacokinetics, Target Engagement, and Pharmacodynamics of BMS-986184 in Patients With Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if single and multiple doses of BMS-986184
      are safe and well tolerated in healthy male and female subjects. The primary purpose of the
      proof of mechanism study is to determine safety and efficacy in patients with ulcerative
      colitis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adverse change in the risk/benefit
  </why_stopped>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">September 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by vital sign measurements</measure>
    <time_frame>Up to 183 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by physical examination findings</measure>
    <time_frame>Up to 183 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by clinical laboratory test results</measure>
    <time_frame>Up to 183 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of safety and tolerability of BMS-986184 as assessed by Electrocardiogram (ECG) assessments</measure>
    <time_frame>Up to 183 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of incidence, severity and outcome of all Adverse Events (AEs)</measure>
    <time_frame>Up to 183 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV doses of BMS-986184 or placebo matching BMS-986184</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986184</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
    <other_name>anti - interferon gamma-induced protein 10(IP-10) antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-986184</intervention_name>
    <arm_group_label>Single Ascending Dose (SAD) - IV Panel</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD) - SC Panel</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) - IV Panel</arm_group_label>
    <arm_group_label>Proof of Mechanism (POM) - IV Panel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Women of childbearing potential must have a negative serum pregnancy test within 24
             hours prior to the start of study drug

          -  Diagnosis of ulcerative colitis confirmed by endoscopic and histologic evidence (if no
             previous confirmation of diagnosis is available or if diagnosis is not conclusive, at
             time of baseline endoscopy, histology must be performed and read locally to confirm
             diagnosis)

        Exclusion Criteria:

          -  Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or
             hepatitis C

          -  Subjects with history of cancer, lymphoproliferative disease, class III or IV
             congestive heart failure, myocardial infarction, unstable angina pectoris, or any
             history of significant ocular disease such as glaucoma or retinal disease

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

